GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » RushNet Inc (OTCPK:RSHN) » Definitions » Return-on-Tangible-Equity

RushNet (RushNet) Return-on-Tangible-Equity : 0.00% (As of . 20)


View and export this data going back to . Start your Free Trial

What is RushNet Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. RushNet's annualized net income for the quarter that ended in . 20 was $ Mil. RushNet's average shareholder tangible equity for the quarter that ended in . 20 was $ Mil. Therefore, RushNet's annualized Return-on-Tangible-Equity for the quarter that ended in . 20 was %.

The historical rank and industry rank for RushNet's Return-on-Tangible-Equity or its related term are showing as below:

RSHN's Return-on-Tangible-Equity is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: -0.72
* Ranked among companies with meaningful Return-on-Tangible-Equity only.

RushNet Return-on-Tangible-Equity Historical Data

The historical data trend for RushNet's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RushNet Return-on-Tangible-Equity Chart

RushNet Annual Data
Trend
Return-on-Tangible-Equity

RushNet Quarterly Data
Return-on-Tangible-Equity

Competitive Comparison of RushNet's Return-on-Tangible-Equity

For the Diagnostics & Research subindustry, RushNet's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


RushNet's Return-on-Tangible-Equity Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, RushNet's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where RushNet's Return-on-Tangible-Equity falls into.



RushNet Return-on-Tangible-Equity Calculation

RushNet's annualized Return-on-Tangible-Equity for the fiscal year that ended in . 20 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: . 20 )  (A: . 20 )(A: . 20 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: . 20 )  (A: . 20 )(A: . 20 )
=/( (+ )/ )
=/
= %

RushNet's annualized Return-on-Tangible-Equity for the quarter that ended in . 20 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: . 20 )  (Q: . 20 )(Q: . 20 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: . 20 )  (Q: . 20 )(Q: . 20 )
=/( (+)/ )
=/
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (. 20) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


RushNet  (OTCPK:RSHN) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


RushNet Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of RushNet's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


RushNet (RushNet) Business Description

Traded in Other Exchanges
N/A
Address
8465 Merchants Way, Suite 206, Orange Park, FL, USA, 32222
RushNet Inc through its subsidiary heliosDX, a National Clinical Reference Laboratory offers High-Complexity Urine Drug Testing (UDT), Behavioral Drug Testing, Allergy Droplet Cards, Oral Fluids, Infectious Disease (PCR), and NGS Genetic Testing. The firm provides physicians individualized customer service, as well as fast and accurate reporting of results. The company invests in its infrastructure with the most efficient scientific proven instruments, and latest software for patient and physician satisfaction. It allows heliosDX to provide physicians fast and accurate reporting meeting. The firm excels in patient and client care through physician designed panels that aid in testing compliance and reporting education.